Cambridge Investment Research Advisors’s Trinity Biotech TRIB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9K	Hold	743	–	–	﹤0.01%	4034
2026 Q1	$12K	Hold	743	–	–	﹤0.01%	3907
2025 Q4	$18K	Hold	743	–	–	﹤0.01%	3793
2025 Q3	$23K	Hold	743	–	–	﹤0.01%	3688
2025 Q2	$14K	Hold	743	–	–	﹤0.01%	3592
2025 Q1	$13K	Hold	743	–	–	﹤0.01%	3477
2024 Q4	$20K	Hold	743	–	–	﹤0.01%	3421
2024 Q3	$25K	Hold	743	–	–	﹤0.01%	3358
2024 Q2	$47K	Hold	743	–	–	﹤0.01%	3221
2024 Q1	$45K	Hold	743	–	–	﹤0.01%	3221
2023 Q4	$48K	Hold	743	–	–	﹤0.01%	3101
2023 Q3	$82K	Hold	743	–	–	﹤0.01%	2991
2023 Q2	$106K	Buy	+743	New	+$108K	﹤0.01%	2995

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

BCM

Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Cambridge Investment Research Advisors's TRIB Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Trinity Biotech (TRIB) position steady in Q2 2026 at 743 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #4034.

Cambridge Investment Research Advisors first reported a position in TRIB in Q2 2023 and has held it in 13 quarters since. The position peaked at $106K in Q2 2023. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

Cambridge Investment Research Advisors held 743 shares of Trinity Biotech worth $9K as of Q2 2026.
Cambridge Investment Research Advisors left its Trinity Biotech share count unchanged in Q2 2026.
Trinity Biotech made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #4034 holding.
Cambridge Investment Research Advisors first reported a position in Trinity Biotech in Q2 2023 and has held it in 13 quarters since.
Cambridge Investment Research Advisors's Trinity Biotech position peaked at $106K in Q2 2023.
19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.